The combination of EGFR-TKIs and anlotinib as a first-line therapy for EGFR-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.

被引：0
|
作者：
He, Zhiyong
Lin, Jinghui
He, Yueming
Zhang, Jing
Yang, Dongyong
Qiu, Wenbin
Lai, Jinhuo
Chen, Xi
Fang, Wenzheng
Ye, Feng
Xu, Tianwen
Wu, Huita
Qiu, Dongfa
Chen, Wujin
Cai, Lifang
Chen, Shengchi
Lin, Qunying
Lin, Li
机构：
[1] Fujian Canc Hosp, Fuzhou, Peoples R China
[2] Fujian Med Univ, Canc Hosp, Fuzhou, Peoples R China
[3] Fujian Med Univ, Hosp Quanzhou Affiliated 1, Quanzhou, Peoples R China
[4] Fujian Med Univ, Affiliated Hosp 2, Dept Pulm & Crit Care Med, Quanzhou, Peoples R China
[5] Fuding Hosp Fujian Prov, Fuding, Peoples R China
[6] Fujian Med Univ, Union Hosp, Dept Med Oncol, Fuzhou, Peoples R China
[7] Fujian Med Univ, 900 Hosp, Joint Logist Team, Clin Med Coll, Fuzhou, Peoples R China
[8] Xiamen Univ, Affiliated Hosp 1, Xiamen, Peoples R China
[9] Fujian Med Coll, Affiliated Hosp 2, Quanzhou, Peoples R China
[10] Xiamen Univ, Zhongshan Hosp, Dept Oncol, Xiamen, Peoples R China
[11] Fujian Med Univ, Sanming Hosp 1, Sanming, Peoples R China
[12] Fujian Univ Tradit Chinese Med, Affiliated Peoples Hosp, Dept Med Oncol, Fuzhou, Peoples R China
[13] Fujian Med Univ, Affiliated Hosp, Putian City Hosp 1, Putian City, Peoples R China
[14] First Hosp Nanping, Nanping, Peoples R China
[15] Putian Univ, Affiliated Hosp, Putian, Peoples R China
[16] FuJian Med Univ, Zhangzhou Affiliated Hosp, Zhangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9030
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9030
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Tislelizumab in combination with anlotinib as first-line treatment for unresectable hepatocellular carcinoma: A single-arm, phase II clinical trial.
    Laoguo, Shi-xue
    Huang, Huasheng
    Zeng, Jie
    Jiang, Yangfeng
    Liu, Cuizhen
    Mo, Ning
    Zhu, GuangZhi
    Ma, Fuchao
    Peng, Tao
    Zeng, Zhiming
    Ma, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 576 - 576
  • [42] The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer
    Xiang, Hai
    Danna, Ding
    Xuefei, Chen
    Zhao, Jinkai
    Jin, Guangjun
    ANTI-CANCER DRUGS, 2024, 35 (05) : 433 - 439
  • [43] Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
    Brueckl, Wolfgang
    Tufman, Amanda
    Huber, Rudolf Maria
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) : 143 - 155
  • [44] The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
    Zhao, Dan
    Chen, Xuejing
    Qin, Na
    Su, Dan
    Zhou, Lijuan
    Zhang, Quan
    Li, Xi
    Zhang, Xinyong
    Jin, Mulan
    Wang, Jinghui
    SCIENTIFIC REPORTS, 2017, 7
  • [45] Amivantamab plus lazertinib vs. osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer
    Hasan, Nazmul
    Nagasaka, Misako
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2025, 19 (03) : 223 - 232
  • [46] The prognostic role of EGFR-TKIs for patients with advanced non-small cell lung cancer
    Dan Zhao
    Xuejing Chen
    Na Qin
    Dan Su
    Lijuan Zhou
    Quan Zhang
    Xi Li
    Xinyong Zhang
    Mulan Jin
    Jinghui Wang
    Scientific Reports, 7
  • [47] First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial
    Zhou, Qing
    Yu, Yan
    Xing, Ligang
    Cheng, Ying
    Wang, Ying
    Pan, Yueyin
    Fan, Yun
    Shi, Jianhua
    Zhang, Guojun
    Cui, Jiuwei
    Zhou, Jianying
    Song, Yong
    Zhuang, Wu
    Ma, Zhiyong
    Hu, Yanping
    Li, Gaofeng
    Dong, Xiaorong
    Feng, Jifeng
    Lu, Shun
    Wu, Jingxun
    Li, Juan
    Zhang, Longzhen
    Wang, Dong
    Xu, Xinhua
    Yang, Tsung-Ying
    Yang, Nong
    Guo, Yubiao
    Zhao, Jun
    Yao, Yu
    Zhong, Diansheng
    Xia, Bing
    Yang, Cheng-Ta
    Zhu, Bo
    Sun, Ping
    Shim, Byoung Yong
    Chen, Yuan
    Wang, Zhen
    Ahn, Myung-Ju
    Wang, Jie
    Wu, Yi-Long
    MED, 2025, 6 (01):
  • [48] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer
    Aguilar-Serra, J.
    Gimeno-Ballester, V
    Pastor-Clerigues, A.
    Milara, J.
    Trigo-Vicente, C.
    Cortijo, J.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (04) : 637 - 646
  • [49] Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
    Guo, Yijia
    Song, Jun
    Wang, Yanru
    Huang, Letian
    Sun, Li
    Zhao, Jianzhu
    Zhang, Shuling
    Jing, Wei
    Ma, Jietao
    Han, Chengbo
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [50] PHASE II TRIAL OF ERLOTINIB AS FIRST-LINE THERAPY IN NON-SMALL CELL LUNG CANCER OVER-EXPRESSING EGFR
    Murphy, Felicity
    Church, David N.
    Medley, Louise
    Davies, J. M.
    Breen, David
    Clelland, Colin
    Mackintosh, David
    Mugalaasi, Hood
    Butler, Rachel
    Talbot, Denis C.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1250 - S1250
12345